Cancer is fierce,
and so is our desire to beat it.
Meet the team that's taking on cancer.
We’re bringing together medical physics, nuclear medicine and radiotherapy in new ways to shift the paradigm of cancer care. Our belief in the difference we can make knows no bounds.
Invention of BgRT
When co-founder Akshay Nanduri visited long-time friend, Sam Mazin at Stanford University, they discussed the possibility of using cancer’s own biology to see and treat multiple tumors at the same time – an idea that would soon become a reality.
RefleXion is born
Just a short time after discussing the idea, Sam Mazin and Akshay Nanduri officially formed RefleXion Medical, a privately-held biotargeting oncology company headquartered in Hayward, CA.
First peer-reviewed publication
RefleXion publishes first paper in Medical Physics, the official journal of the American Association of Physicists in Medicine, that describes the RefleXion machine concept and the original BgRT approach for simulated lung and prostate cancers. It established the foundation for RefleXion’s clinical development program.
Funding the dream
RefleXion Medical successfully raised $11.6 million in Series A financing led by Paris-based Sofinnova Partners and joined by Pfizer Venture Investments (PVI), and Venrock.
Significant innovation in localized cancer treatment
With a bold mission and the drive to build a high-performing business, RefleXion captured the interest of blue-chip investors, all committed to advancing a new modality in cancer care, especially for stage-four cancer patients.
To date, RefleXion has raised nearly $300M from premier investment firms including PSP Investments, TPG Growth / The Rise Fund, KCK Group, Sofinnova Partners, Venrock, T. Rowe Price, and global pharmaceutical leaders, Pfizer Ventures, Johnson & Johnson Innovation, and Oxford Capital.
The National Cancer Institute (NCI) also provided grant funding through its Small Business Innovation Research (SBIR) Program.